#ASH20: In a multiple myeloma showdown, Regeneron marches out new PhI data for its BCMA bispecific

After kicking off a multiple myeloma rivalry with Bristol Myers Squibb at last year’s ASH, Regeneron is back with an updated safety and durability analysis from the first-in-human study of its BCMA bispecific.

In the Phase I portion of a Phase I/II dose-escalation study, researchers noted a 6-month median duration of response, Regeneron announced at ASH 2020. “We feel very encouraged,” Andres Sirulnik, senior VP of translational and clinical sciences and hematology, said of REGN5458. “The drug is very well tolerated.”